Compare iShares Silver Trust (SLV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs TG Therapeutics Inc — how do they compare? iShares Silver Trust trades at $59.82, while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | TGTX | |
|---|---|---|
52-Week High | $105.57 | $59.06 |
52-Week Low | $37.41 | $26.94 |
Market Cap | — | $8.36B |
Sector | — | Health |
Enterprise Value | — | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, trades at $59.37, down 0.75% amid a bearish technical signal. Key support lies at $58, with resistance at $60. Recent news highlights silver's volatility driven by Federal Reserve policy uncertainty, dollar fluctuations, and geopolitical tensions. The ETF, with $33.8 billion in assets under management, lacks traditional financial ratios as it tracks physical silver prices rather than corporate earnings.
Outlook remains cautious due to bearish technical indicators and macroeconomic headwinds like inflation and rate hikes. Opportunities exist for income-focused investors using options strategies, but risks include silver's sensitivity to industrial demand shifts and Fed policy. Institutional buying, such as Concurrent Investment Advisors' 32.9% stake increase, provides some support.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
